L3Harris Technologies Inc vs Nuwellis Inc — how do they compare? L3Harris Technologies Inc trades at $290.9 (market cap $53.26B), while Nuwellis Inc trades at $1.4 (market cap $542.80K). The key difference: L3Harris Technologies Inc is far larger — about 98120.9× Nuwellis Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LHX | NUWE | |
|---|---|---|
Market Cap | $53.26B | $542.80K |
Sector | Industrials | Technology |
52-Week High | $378.48 | $220.50 |
52-Week Low | $270.21 | $1.42 |
Enterprise Value | $63.71B | -$1.27M |
Dividend Yield | 1.75% | — |
Signals from Pluang's Aura AI — not financial advice
LHX trades at $290.66, up 0.32% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with revenue up 8% and a record $42 billion backlog. Recent news highlights contract wins, including a U.S. Space Force satellite deal and PAC-3 production expansion, supporting growth prospects. Fundamentals show steady revenue growth to $21.87 billion in 2025 and improving net margins, though valuation ratios like P/E of 28.89 are elevated relative to historical averages.
Outlook is positive with analyst consensus favoring buys (73%) and a $319.33 price target implying ~10% upside. Risks include execution on large contracts, debt levels, and geopolitical dependencies. The stock offers a dividend yield near 1.7%, with cash flow strength supporting shareholder returns amid defense sector tailwinds.
NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.
Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →